We found that neutralizing IL-1β in Acsl4 TG mice significantly reduced TAC-induced cardiac hypertrophy (Supplementary Fig. 11b), improved cardiac systolic performance (Supplementary Fig. 11c, d), prevented cardiomyocyte hypertrophy (Supplementary Fig. 11e), and reduced all three markers of cardiac hypertrophy (Supplementary Fig. 11f, g). This evidence concerns the gene ACSL4 and cardiac hypertrophy.